Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
3.570
+0.040 (1.13%)
At close: May 21, 2026, 4:00 PM EDT
3.590
+0.020 (0.56%)
After-hours: May 21, 2026, 7:41 PM EDT
Larimar Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Larimar Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $15.88. The average 1-year stock price forecast is 344.82% higher than the current stock price, while the lowest is $7.00 (+96.08%) and the highest is $26 (+628.29%).
Price Target: $15.88 (+344.82%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Larimar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $13 → $12 | Buy | Maintains | $13 → $12 | +236.13% | May 18, 2026 |
| Wedbush | Wedbush | Buy Maintains $12 → $13 | Buy | Maintains | $12 → $13 | +264.15% | Mar 20, 2026 |
| Wedbush | Wedbush | Buy Maintains $11 → $12 | Buy | Maintains | $11 → $12 | +236.13% | Mar 3, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $12 → $14 | Strong Buy | Maintains | $12 → $14 | +292.16% | Feb 25, 2026 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +208.12% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
61.42M
EPS This Year
-1.85
from -2.27
EPS Next Year
-1.37
from -1.85
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 200.9M | ||||||
| Avg | n/a | 61.4M | ||||||
| Low | n/a | 4.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.49 | -0.70 | ||||||
| Avg | -1.85 | -1.37 | ||||||
| Low | -2.39 | -2.30 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.